FDA approves Johnson & Johnson's nasal spray for depression

FDA approves standalone use of J&J’s ketamine-derived depression treatment
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used as a standalone treatment for patients with severe depression, the company said on Tuesday.
FDA approves Spravato, first monotherapy nasal spray to treat depression
The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder,
J&J's ketamine-derived nasal spray approved by FDA to treat depression
Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.
US FDA approves J&J's ketamine-based therapy to treat depression
The U.S. Food and Drug Administration approved Johnson & Johnson's ketamine-based nasal spray Spravato to treat adults with major depressive disorder, the company said on Tuesday. The approval paves the way for use of Spravato in patients whose disease has stopped responding to at least two oral anti-depressants.
FDA approves first nasal spray for major depression disorder
The U.S. Food and Drug Administration on Tuesday approved the first nasal spray that will help with treating major depressive disorder.
JNJ's SNDA For Spravato Monotherapy Gets FDA Approval For Treatment-Resistant Depression
Tuesday announced that the U.S. Food and Drug Administration has approved supplemental New Drug Application or sNDA for Spravato, a monotherapy for adults with treatment-resistant depression, a psychiatric disorder.
Johnson & Johnson Gets FDA OK For Spravato as Monotherapy
Johnson & Johnson has won Food and Drug Administration expanded approval of its Spravato nasal spray as a lone therapy for adults with treatment-resistant depression. J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
FDA proposes mandatory front-of-package nutrition labels to combat spike in chronic diseases
The U.S. Food and Drug Administration (FDA) is demanding increased, in-your-face food transparency when it comes to nutrition ...
STAT22h
Three former FDA officials: Here’s what Trump and his nominees need to know
The FDA is the leading science-based consumer protection agency in the world. Three former senior officials write about what ...
FDA makes key decision on Zyn nicotine pouches
In a statement, the FDA said it has authorized the marketing and sale of Philip Morris International’s Zyn nicotine pouches.
RFK Jr. wants to improve Americans’ health. Here’s some advice from the outgoing FDA chief
Robert F. Kennedy Jr. has big plans for the FDA if he's confirmed as Secretary of Health and Human Services. FDA Commissioner ...
STAT17h
A next-generation form of chemotherapy wins FDA approval
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Food Safety News4h
Outgoing FDA Commissioner Robert Califf discusses agency’s uncertain future
Dr. Robert M. Califf bid farewell to his role as Commissioner of the U.S. Food and Drug Administration in a reflective post ...
Healio15h
FDA approves Datroway for advanced breast cancer
The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...
More than a dozen cats dead or sickened by bird flu in raw pet food, FDA says
More than a dozen cats have been killed or sickened by bird flu that is spreading in raw food products, the Food and Drug ...